Shares of China Biologic Products (NASDAQ: CBPO) are falling today, down 15.9% as of 10:58 a.m. EDT, after the company announced updates regarding the two buyout offers it has received since June.The blood plasma leader said that its board of directors received a letter on Aug. 23 from CITIC Capital Holdings in which the Chinese financial firm withdrew its June 2018 proposal to acquire the company for $110 per share (more on that below).